Gottlieb AB, et al. - Experts presented the patient-reported outcomes of patients with psoriatic arthritis (PsA) treated with ixekizumab up to 52 weeks. In this study they randomized biologic-naïve patients with active PsA to ixekizumab 80 mg every 4 weeks or every 2 weeks after a 160 mg starting dose, adalimumab 40 mg every 2 weeks or placebo during the initial 24-week double-blind treatment period. As per data, a significant improvement in the skin symptoms, health-related quality of life and work productivity was seen with ixekizumab in biologic-naïve patients with active PsA.